Complete remission of metastatic pheochromocytoma in 123I-metaiodobenzylguanidine scintigraphy after a single session of 131I-metaiodobenzylguanidine therapy: A case report

被引：1

作者：

Sugino T. ^{[1
]}

Ando R. ^{[1
]}

Unno R. ^{[1
]}

Iida K. ^{[1
]}

Naiki T. ^{[1
]}

Hamamoto S. ^{[1
]}

Mizuno K. ^{[1
]}

Okada A. ^{[1
]}

Umemoto Y. ^{[1
]}

Kawai N. ^{[1
]}

Tozawa K. ^{[1
]}

Hayashi Y. ^{[1
]}

Inaki A. ^{[2
]}

Kayano D. ^{[2
]}

Kinuya S. ^{[2
]}

Yasui T. ^{[1
]}

机构：

[1] Department of Nephro-urology, Nagoya City University Graduate, School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya

[2] Department of Nuclear Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa

来源：

BMC Research Notes | / 10卷 / 1期

关键词：

!sup]131[!/sup]I-metaiodobenzylguanidine; Adrenal gland neoplasm; Germ-line mutation; Malignant pheochromocytoma; Neuroendocrine tumor;

D O I：

10.1186/s13104-017-3095-6

中图分类号：

学科分类号：

摘要：

Background: Pheochromocytomas are rare neuroendocrine tumors, with a malignancy frequency of approximately 10%. The treatment of malignant pheochromocytoma is palliative, and the traditional management strategy has limited efficacy. Furthermore, no clear criteria exist for the treatment of metastatic pheochromocytoma, especially for unresectable lesions. We report a case of complete remission of metastatic pheochromocytoma in 123I-metaiodobenzylguanidine (MIBG) scintigraphy after a single session of 131I-MIBG therapy. Case presentation: A 61-year-old woman had a right adrenal grand tumor and lymph node metastasis on the hilum of the right kidney, both of which incorporated MIBG. After surgery, immunostaining of a tumor specimen showed expression of the tumor makers chromogranin and synaptophysin. One year postoperatively, abdominal computed tomography revealed a local recurrence and retroperitoneal lymph node swelling. The local recurrence was positive for MIBG uptake, whereas the swollen retroperitoneal lymph nodes were negative. She underwent surgery again, but the local recurrence was unresectable because of rigid adhesion to the surrounding tissue. Immunostaining of an intraoperatively extracted swollen retroperitoneal lymph node showed expression of tumor markers. The patient then underwent a single session of 131I-MIBG therapy (7.4 GBq, 200 mCi), after which the residual lesions no longer incorporated MIBG, and a complete response in 123I- metaiodobenzylguanidine (MIBG) scintigraphy was achieved. The 131I-MIBG treatment was repeated 6 months later. None of the lesions were positive for MIBG uptake. Conclusions: 131I-MIBG therapy efficaciously treats unresectable lesions that are positive for MIBG uptake. © 2017 The Author(s).

引用

共 15 条

[1]

Adler J.T., Meyer-Rochow G.Y., Chen H., Benn D.E., Robinson B.G., Sippel R.S., Et al., Pheochromocytoma: Current approaches and future directions, Oncologist, 13, pp. 779-793, (2008)

[2]

Chrisoulidou A., Kaltsas G., Ilias I., Grossman A.B., The diagnosis and management of malignant phaeochromocytoma and paraganglioma, Endocr Relat Cancer, 14, pp. 569-585, (2007)

[3]

Parenti G., Zampetti B., Rapizzi E., Ercolino T., Giache V., Mannelli M., Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma, J Oncol, 2012, (2012)

[4]

Pacak K., Eisenhofer G., Ahlman H., Bornstein S.R., Gimenez-Roqueplo A.P., Grossman A.B., Et al., International symposium on pheochromocytoma. Pheochromocytoma: Recommendations for clinical practice from the first international symposium. October 2005, Nat Clin Pract Endocrinol Metab, 3, pp. 92-102, (2007)

[5]

Ayala-Ramirez M., Feng L., Johnson M.M., Ejaz S., Habra M.A., Rich T., Et al., Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: Primary tumor size and primary tumor location as prognostic indicators, J Clin Endocrinol Metab, 96, pp. 717-725, (2011)

[6]

Baudin E., Habra M.A., Deschamps F., Cote G., Dumont F., Cabanillas M., Et al., Therapy of endocrine disease: Treatment of malignant pheochromocytoma and paraganglioma, Eur J Endocrinol, 171, pp. R111-R122, (2014)

[7]

Krempf M., Lumbroso J., Mornex R., Brendel A.J., Wemeau J.L., Delisle M.J., Et al., Use of m-[131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma, J Clin Endocrinol Metab, 72, pp. 455-456, (1991)

[8]

Gedik G.K., Hoefnagel C.A., Bais E., Olmos R.A., <sup>131</sup>I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma, Eur J Nucl Med Mol Imaging, 35, pp. 725-733, (2008)

[9]

Huang H., Abraham J., Hung E., Averbuch S., Merino M., Steinberg S.M., Et al., Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: Recommendation from a 22-year follow-up of 18 patients, Cancer, 113, pp. 2020-2028, (2008)

[10]

Tanabe A., Naruse M., Nomura K., Tsuiki M., Tsumagari A., Ichihara A., Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma, Horm Cancer, 4, pp. 103-110, (2013)

← 1 2 →